Longevity & AgingSemaglutide Cuts Weight by 9 kg and Reverses Prediabetes in Schizophrenia Patients
The HISTORI trial randomized 154 adults with schizophrenia, prediabetes, and obesity to once-weekly semaglutide (1.0 mg) or placebo for 30 weeks. Semaglutide significantly reduced HbA1c by 0.46%, with 81% of treated patients achieving normal glucose levels versus 19% on placebo. Body weight fell by a mean of 9.21 kg. HDL cholesterol improved and triglycerides declined. Physical quality of life improved meaningfully, and crucially, psychiatric symptoms (PANSS-6) and mental quality of life were unaffected. Gastrointestinal side effects were more common with semaglutide, but serious adverse event rates were similar between groups. This is the first rigorous evidence that GLP-1 receptor agonists can safely address cardiometabolic risk in this vulnerable psychiatric population.
